Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Private label insole and pillow OEM Vietnam

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Taiwan OEM insole and pillow supplier

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Indonesia custom insole OEM supplier

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Taiwan pillow ODM development factory

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Taiwan eco-friendly graphene material processing

Adjacent cells freely exchange small molecules and ions with each other through channels made from proteins called connexins. Dysfunction in this important type of intercellular communication has been linked to a variety of diseases, including those of the heart and peripheral nervous system. Thus, connexins are important drug targets. Credit: Laura Canil Researchers have advanced their understanding of how drugs interact with connexin molecules. Connexins create channels that enable direct communication between adjacent cells. Dysfunctions in these channels play a role in neurological and cardiac disorders. This enhanced knowledge of drug binding and action on connexins could aid in developing treatments for these diseases. Today we use many electronic means to communicate, but sometimes dropping a note in a neighbor’s letter box or leaving a cake on a doorstep is most effective. Cells too have ways to send direct messages to their neighbors. Adjacent cells can communicate directly through relatively large channels called gap junctions, which allow cells to freely exchange small molecules and ions with each other or with the outside environment. In this way, they can coordinate activities in the tissues or organs that they compose and maintain homeostasis. Such channels are created from proteins known as connexins. Six connexins situated in the cell membrane create a hemichannel; this hemichannel joins with a hemichannel in a neighboring cell to create a two-way channel. When connexin channels do not work properly, they cause changes in intercellular communication that have been linked to many different diseases. These include cardiac arrhythmias, diseases of the central nervous system such as epilepsy, neurodegenerative diseases, and cancer. As a result, the search is on for drugs that target connexins. Yet, understanding of the structure of connexins and how drugs bind to connexin channels to block or activate them is limited. Indeed, of the twenty-one types of connexins known to exist in humans, few of them are currently evaluated as drug targets. An Explanation for Antimalarial Side Effects? Now, researchers from PSI, ETH Zurich, and the University of Geneva have deepened our understanding of connexin channels and how they bind to drug molecules. The study is published in the journal Cell Discovery. The connexin they studied is known as connexin-36, or Cx36 for short. Cx36 plays important roles in the pancreas and the brain, respectively controlling insulin secretion and neuronal activity. Heightened levels of Cx36 channels have been found in patients suffering epilepsy following traumatic brain injury. Here, it is thought that the increased activity of the gap junction channels causes neurons to die. Therefore, the team was interested in drugs that inhibit the channels. The team studied Cx36 bound to the antimalarial drug mefloquine (brand name Lariam). The drug is known to act on the parasites that cause malaria when they enter the bloodstream from infected mosquitos. However, research has indicated that the mefloquine also binds to Cx36 in our cells, potentially explaining some of the well-known severe neuropsychiatric side effects of the drug. Using cryo-electron microscopy, the research team captured high-resolution structures of Cx36 gap junction channels with and without the presence of mefloquine. They saw how the drug molecule binds to each of the six connexins composing the channel. The binding site is buried within the pore of the channel, and so, when six molecules bind, they effectively close the channel. Computer simulations by collaborators at the University of Geneva helped the team understand the effect that mefloquine binding would have on the ability of the channel to permit ions to through. In this way, they showed that binding of the drug restricts the flow of solutes through the channel. A Starting Point for Structure-Based Drug Discovery in Connexins The researchers hope that this new structural knowledge will be a starting point for developing new drugs with greater specificity for particular connexin channels. “Our study shows how a drug molecule lands in the pore of the channel and, through our simulations, gives a plausible explanation for how the drug inhibits the channel,” says Volodymyr Korkhov, group leader at PSI and associate professor at the ETH Zurich, who led the study. “This is relevant not only to Cx36, but to the wider question of connexin–drug interactions.” The latest findings complement other research activities into connexins from the PSI/ETHZ group: notably, the structure of connexin 43 in the closed conformation and how structure and function are linked in connexin 32, which plays a role in the peripheral nervous system. Reference: “Structural basis of connexin-36 gap junction channel inhibition” by Xinyue Ding, Simone Aureli, Anand Vaithia, Pia Lavriha, Dina Schuster, Basavraj Khanppnavar, Xiaodan Li, Thorsten B. Blum, Paola Picotti, Francesco L. Gervasio and Volodymyr M. Korkhov, 18 June 2024, Cell Discovery. DOI: 10.1038/s41421-024-00691-y

The research demonstrates that many cells in the inner ear react simultaneously to low-frequency sound. New Findings on Low-Frequency Hearing May Enhance Cochlear Implants The way humans experience music and speech differs from what was previously thought. This is the finding of a study conducted by researchers from Linköping University in Sweden and Oregon Health and Science University in the United States. The findings, which have recently been published in the journal Science Advances could improve cochlear implant design. We are sociable beings. We value hearing other people’s voices, and we use our hearing to recognize and experience human speech and voices. Sound that enters the outer ear is transmitted by the eardrum to the spiral-shaped inner ear, also known as the cochlea. The cochlea is home to the outer and inner hair cells, which are the sensory cells of hearing.  The inner hair cells’ “hairs” bend as a result of the sound waves, delivering a signal through the nerves to the brain, which interprets the sound we hear. Anders Fridberger and Pierre Hakizimana measure vibrations in the hearing organ. Credit: Emma Busk Winquist/Linköping University We have believed for the last 100 years that each sensory cell has its own “optimal frequency” (a measure of the number of sound waves per second). This frequency elicits the strongest response from the hair cell. This implies that a sensory cell with an optimum frequency of 1000 Hz will respond significantly less strongly to sounds with slightly lower or higher frequencies. It has also been thought that all parts of the cochlea function similarly. However, a research team has revealed that this is not the case for sensory cells that process low-frequency sound with frequencies less than 1000 Hz. Vowel sounds in human speech fall into this category. Low-Frequency Sounds in Robust Hearing “Our study shows that many cells in the inner ear react simultaneously to low-frequency sound. We believe that this makes it easier to experience low-frequency sounds than would otherwise be the case since the brain receives information from many sensory cells at the same time,” says Anders Fridberger, professor in the Department of Biomedical and Clinical Sciences at Linköping University. Anders Fridberger conducting research. Credit: Emma Busk Winquist/Linköping University The scientists believe that this construction of our hearing system makes it more robust. If some sensory cells are damaged, many others remain that can send nerve impulses to the brain. Implications for Cochlear Implant Design Anders Fridberger, professor at Linköping University. Credit: Emma Busk Winquist/Linköping University It is not only the vowel sounds of human speech that lie in the low-frequency region: many of the sounds that go to make up music also lie here. Middle C on a piano, for example, has a frequency of 262 Hz. These results may eventually be significant for people with severe hearing impairments. The most successful treatment currently available in such cases is a cochlear implant, in which electrodes are placed into the cochlea. “The design of current cochlear implants is based on the assumption that each electrode should only give nerve stimulation at certain frequencies, in a way that tries to copy what was believed about the function of our hearing system. We suggest that changing the stimulation method at low frequencies will be more similar to the natural stimulation, and the hearing experience of the user should in this way be improved,” says Anders Fridberger. The researchers now plan to examine how their new knowledge can be applied in practice. One of the projects they are investigating concerns new methods to stimulate the low-frequency parts of the cochlea. These results come from experiments on the cochlea of guinea pigs, whose hearing in the low-frequency region is similar to that of humans. Reference: “Best frequencies and temporal delays are similar across the low-frequency regions of the guinea pig cochlea” by George Burwood, Pierre Hakizimana, Alfred L Nuttall and Anders Fridberger, 23 September 2022, Science Advances. DOI: 10.1126/sciadv.abq2773 The study was funded by the U.S. National Institutes of Health and the Swedish Research Council.

Researchers have mapped the genetic and cellular makeup of human and nonhuman primate brains, providing deeper insights into brain functions and potential treatments for disorders. This research, part of The BRAIN Initiative®, spans 24 papers and holds promise for transformative advances in neuroscience. Incredibly detailed cell maps help pave the way for a new generation of treatments. A group of international scientists have mapped the genetic, cellular, and structural makeup of the human brain and the nonhuman primate brain. This understanding of brain structure, achieved by funding through the National Institutes of Health’s Brain Research Through Advancing Innovative Neurotechnologies® Initiative, or The BRAIN Initiative®, allows for a deeper knowledge of the cellular basis of brain function and dysfunction, helping pave the way for a new generation of precision therapeutics for people with mental disorders and other disorders of the brain. The findings appear in a compendium of 24 papers across Science, Science Advances, and Science Translational Medicine. “Mapping the brain’s cellular landscape is a critical step toward understanding how this vital organ works in health and disease,” said Joshua A. Gordon, M.D., Ph.D., director of the National Institute of Mental Health. “These new detailed cell atlases of the human brain and the nonhuman primate brain offer a foundation for designing new therapies that can target the specific brain cells and circuits involved in brain disorders.” Key Findings and Insights The 24 papers in this latest BRAIN Initiative Cell Census Network (BICCN) collection detail the exceptionally complex diversity of cells in the human brain and the nonhuman primate brain. The studies identify similarities and differences in how cells are organized and how genes are regulated in the human brain and the nonhuman primate brain. For example: Three papers in the collection present the first atlas of cells in the adult human brain, mapping the transcriptional and epigenomic landscape of the brain. The transcriptome is the complete set of gene readouts in a cell, which contains instructions for making proteins and other cellular products. The epigenome refers to chemical modifications to a cell’s DNA and chromosomes that alter the way the cell’s genetic information is expressed. In another paper, a comparison of the cellular and molecular properties of the human brain and several nonhuman primate brains (chimpanzee, gorilla, macaque, and marmoset brains) revealed clear similarities in the types, proportions, and spatial organization of cells in the cerebral cortex of humans and nonhuman primates. Examination of the genetic expression of cortical cells across species suggests that relatively small changes in gene expression in the human lineage led to changes in neuronal wiring and synaptic function that likely allowed for greater brain plasticity in humans, supporting the human brain’s ability to adapt, learn, and change. A study exploring how cells vary in different brain regions in marmosets found a link between the properties of cells in the adult brain and the properties of those cells during development. The link suggests that developmental programming is embedded in cells when they are formed and maintained into adulthood and that some observable cellular properties in an adult may have their origins very early in life. This finding could lead to new insights into brain development and function across the lifespan. An exploration of the anatomy and physiology of neurons in the outermost layer of the neocortex—part of the brain involved in higher-order functions such as cognition, motor commands, and language—revealed differences in the human brain and the mouse brain that suggest this region may be an evolutionary hotspot, with changes in humans reflecting the higher demands of regulating humans’ more complex brain circuits. The core aim of the BICCN, a groundbreaking effort to understand the brain’s cellular makeup, is to develop a comprehensive inventory of the cells in the brain—where they are, how they develop, how they work together, and how they regulate their activity—to better understand how brain disorders develop, progress, and are best treated. “This suite of studies represents a landmark achievement in illuminating the complexity of the human brain at the cellular level,” said John Ngai, Ph.D., director of the NIH BRAIN Initiative. “The scientific collaborations forged through BICCN are propelling the field forward at an exponential pace; the progress—and possibilities—have been simply breathtaking.” The census of brain cell types in the human brain and the nonhuman primate brain presented in this paper collection serves as a key step toward developing the brain treatments of the future. The findings also set the stage for the BRAIN Initiative Cell Atlas Network, a transformative project that, together with two other large-scale projects—the BRAIN Initiative Connectivity Across Scales and the Armamentarium for Precision Brain Cell Access—aim to revolutionize neuroscience research by illuminating foundational principles governing the circuit basis of behavior and informing new approaches to treating human brain disorders.

DVDV1551RTWW78V